The Technical Analyst
Bolt Biotherapeutics, [BOLT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Bolt Biotherapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.52% $1.160
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 44.23 mill |
| EPS: | -1.830 |
| P/E: | -0.630 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 38.13 mill |
| Avg Daily Volume: | 0.133 mill |
| RATING 2024-04-25 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.630 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.11x |
| Company: PE -0.630 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.069 - 1.251 ( +/- 7.84%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-04 | Yonehiro Grant | Buy | 235 000 | Stock Option (Right to Buy) |
| 2024-03-04 | Perez Edith A. | Buy | 235 000 | Stock Option (Right to Buy) |
| 2024-03-04 | Schatzman Randall C | Buy | 654 000 | Stock Option (Right to Buy) |
| 2024-03-04 | Quinn William P. | Buy | 235 000 | Stock Option (Right to Buy) |
| 2023-12-31 | Yonehiro Grant | Buy | 0 |
| INSIDER POWER |
|---|
| 72.58 |
| Last 93 transactions |
| Buy: 5 349 325 | Sell: 1 125 168 |
Forecast:
16:00 - $1.160
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.160
Forecast 2: 16:00 - $1.160
Forecast 3: 16:00 - $1.160
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.160 (-2.52% ) |
| Volume | 0.0133 mill |
| Avg. Vol. | 0.133 mill |
| % of Avg. Vol | 10.00 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BOLT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Last 10 Buy Signals
| Date | Signal | @ |
|---|---|---|
| ATEA.OL | Apr 26 - 07:11 | NOK137.40 |
| RECSI.OL | Apr 26 - 07:10 | NOK10.92 |
| GOGL.OL | Apr 26 - 07:09 | NOK153.50 |
| WANETHUSD | Apr 26 - 07:23 | 3 101.68 |
| MING.OL | Apr 26 - 07:08 | NOK142.80 |
| ULTI.OL | Apr 26 - 07:07 | NOK7.10 |
| SOFF.OL | Apr 26 - 07:05 | NOK41.74 |
| ETHXUSD | Apr 26 - 07:18 | 3 221.33 |
| SOON.OL | Apr 26 - 07:03 | NOK67.20 |
| NORCO.OL | Apr 26 - 07:03 | 26.65 |
Latest Press Releases
2024-03-21 16:05:00 - Press Release
Bolt Biotherapeutics Reports Fourth Quarter And Full-year 2023 Financial Results And Provides Business Update
– bdc-1001 (trastuzumab imbotolimod) phase 2 studies in four her2-positive tumor types advancing toward 2024 milestones– bdc-3042 phase 1 study successfully cleared safety assessments in the first three dose level cohorts – cash balance of $128.6 million as of december 31, 2023, anticipated to fund key milestones through late 2025
2024-02-27 07:00:00 - Press Release
Bolt Biotherapeutics To Present At The Td Cowen 44th Annual Healthcare Conference
Redwood city, calif., feb. 27, 2024 (globe newswire) -- bolt biotherapeutics (nasdaq: bolt), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the td cowen 44th annual healthcare conference on tuesday, mar. 5, at 2:50 p.m. edt (11:50 a.m. pdt) in boston, massachusetts.
2023-12-05 07:00:00 - Press Release
Bolt Biotherapeutics Enrolls First Patient In Phase 2 Clinical Study Evaluating Bdc-1001 In Patients With Her2-positive Breast Cancer Previously Treated With Enhertu®
Redwood city, calif., dec. 05, 2023 (globe newswire) -- bolt biotherapeutics, inc. (nasdaq: bolt), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed in the phase 2 clinical trial investigating bdc-1001, a her2-targeting boltbody™ immune-stimulating antibody conjugate (isac), as a single agent and in combination with the her2-targeting antibody pertuzumab.
2023-11-09 16:05:00 - Press Release
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results And Provides Business Update
Redwood city, calif., nov. 09, 2023 (globe newswire) -- bolt biotherapeutics (nasdaq: bolt), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended september 30, 2023, and provided an update on the continued advancement of its clinical programs.
2023-10-23 10:30:00 - Press Release
Bolt Biotherapeutics Presents Updated Clinical Data From Phase 1 Dose-escalation Trial Of Bdc-1001 As Monotherapy And In Combination With Nivolumab In Her2-expressing Tumors At Esmo 2023 Congress
Redwood city, calif., oct. 23, 2023 (globe newswire) -- bolt biotherapeutics (nasdaq: bolt), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated data from its phase 1 dose-escalation trial of bdc-1001 at the european society for medical oncology (esmo) 2023 congress, being held in madrid, spain and virtually from october 20-24, 2023.
Latest News
2024-02-27 07:00:00 - GlobeNewsWire
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, Mar. 5, at 2:50 p.m. EDT (11:50 a.m. PDT) in Boston, Massachusetts.
2023-10-16 07:00:00 - GlobeNewsWire
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today announced that updated clinical data from its Phase 1/2 dose-escalation study of BDC-1001 will be presented in a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held in Madrid, Spain and virtually from October 20-24, 2023.
2023-09-05 16:15:00 - GlobeNewsWire
Bolt Biotherapeutics to Participate in September Investor Conferences
REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September:
2023-07-31 17:27:00 - GlobeNewsWire
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2023 on Monday, August 7, 2023, at 10:00 a.m. EDT (7:00 a.m. PDT).
2023-04-26 10:00:00 - GlobeNewsWire
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials
2023-03-14 16:30:00 - GlobeNewsWire
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
REDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with new preclinical data for BDC-3042, a Dectin-2-targeting agonistic antibody, at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2023. The conference is being held at the Orange County Convention Center in Orlando, Fla. from April 14-19, 2023.
2023-02-28 08:00:00 - GlobeNewsWire
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will present a company overview at the Cowen 43rd Annual Healthcare Conference on Tuesday, March 7, 2023, at 2:50 p.m. EST (11:50 a.m. PST) in Boston, Mass.
2023-02-01 08:00:00 - GlobeNewsWire
Bolt Biotherapeutics to Present at February Investor Conferences
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in February:
2022-08-31 07:30:00 - GlobeNewsWire
Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 12:20 p.m. ET (9:20 a.m. PT) in New York, New York.
2022-08-26 15:24:15 - Seeking Alpha
Bolt Biotherapeutics: A Promised Follow Up
Today, we post a promised follow-up on early stage biotech concern Bolt Biotherapeutics. The company has suffered some setbacks over the past year, but the stock now trades for approximately one-third of the cash on its balance sheet.